Overview

Nab-PCE vs PC for MM After Failure of Anti-PD-1

Status:
Recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

This is a randomized controlled clinical trial of nab-paclitaxel + carboplatin - Endostatin for advanced melanoma after failure of PD-1 therapy. The aim was to evaluate the efficacy and safety of nab-paclitaxel+carboplatin - endostatin versus combination of paclitaxel and carboplatin in patients with advanced melanoma after failure of PD-1 therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Beijing Cancer Hospital

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Endostatins
Paclitaxel